ARAMIS Patient Summary

 PHEN Clinical Trials Rally


A clinical research study for patients with prostate cancer that has not spread beyond the prostate

Bayer HealthCare is seeking men who have prostate cancer to participate in a research study of an investigational drug. The purpose of the ARAMIS trial is to determine the safety and effectiveness of an investigational drug in delaying prostate cancer spreading from the prostate. This study is enrolling patients with prostate cancer that is at risk of progressing, but has not already spread to other areas of the body. Eligible patients must have rising prostate specific antigen (PSA) values without spread of their prostate cancer to other areas of the body.

If you are currently receiving hormone therapy, your treatment will continue and in addition you will receive either the investigational medication or placebo. Two out of every 3 patients will receive investigational medication and the assignment to the medication will be random.

To learn more about the ARAMIS trial and to find out if you may be eligible, please visit:http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php (Trial Number: 17712) or www.clinicaltrials.gov (Study Identifier: NCT02200614) 


  • Use the "clinical trials glossary" and "dictionary" for words, phrases and treatments that you may not understand.
PHEN Contact: 617-481-4020 x3

ARAMIS Sponsor:
Bayer; Contact: 646-776-7532 or 844-229-3710 (toll free), email: 
Bayer@emergingmed.com

 
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.



Go Back





PHEN,Inc. © 2017 All rights reserved